Navigation Links
Simple Test Accurately Predicts Risk of Serious Jaundice in Newborns
Date:1/11/2008

PHILADELPHIA, Jan. 11 /PRNewswire-USNewswire/ -- A simple test can accurately identify which newborn babies are at risk for developing dangerous levels of jaundice, according to researchers at The Children's Hospital of Philadelphia.

While neonatal jaundice, a yellowing of the skin caused by a buildup of a blood product called bilirubin, is common in newborns and usually disappears on its own, it can progress to brain damage in a small fraction of cases.

The American Academy of Pediatrics currently recommends two options, used alone or in combination, to assess an infant's risk of developing severe hyperbilirubinemia: a predischarge measurement of the bilirubin level and a screening checklist of risk factors such as intended method of feeding, siblings with history of jaundice, and race.

The Children's Hospital researchers say that the predischarge bilirubin measurement, combined with the baby's gestational age, is the most accurate method for predicting whether the newborn is at risk.

Their findings are published in the January 2008 issue of the journal Pediatrics. Children's Hospital physicians studied outcomes for 823 newborns admitted to the Hospital of the University of Pennsylvania in Philadelphia between September 2004 and October 2005.

"The challenge facing every pediatrician who takes care of newborn babies is to identify those infants they send home that will develop a bilirubin level that could cause injury," said Ron Keren, M.D., M.P.H., a pediatrician at Children's Hospital and the lead author of the study. "We found that by measuring the bilirubin in every baby, and combining that information with the baby's gestational age, you could accurately predict which infants are at very high risk and which ones are at very low risk."

This screening method should allow pediatricians to determine which newborns should stay in the hospital for monitoring, which may go home and return the next day for an
'/>"/>

SOURCE The Children's Hospital of Philadelphia
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Synvista Announces New Data Showing Haptoglobin Type Predicts Effectiveness of Tight Glycemic Control on Cardiovascular Outcomes in Patients with Diabetes
2. DNA Test Predicts Harmful Effects of Cancer Drug
3. Olympic Gold Medalist Kristi Yamaguchi Joins American Lung Association of Michigan to Address Seriously Low Vaccination Rates; Urge Metro-Detroiters to Get Immunized This Season
4. Despite Serious Health Risks, One in Three Adults with Heart Disease Does Not Believe They Need a Flu Shot This Year
5. Mayo Clinic Clarifies Diagnosis and Treatment for Rare, Serious Blood Vessel Disease of Brain and Spinal Cord
6. Seriously Low Vaccination Rates Cause Experts to Call for Increased Immunization Before Influenza Season Peaks
7. New Topical Therapy Safely Treats Serious Skin Infections Without Systemic Side Effects
8. New Research Shows Masimo Perfusion Index (PI) Effective in the Noninvasive Detection of Congenital Heart Defects (CHD) in Newborns
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)LAKE FOREST, Ill., Dec. 4 Hospira, Inc. (NYSE: HSP ), a leading global specialty pharmaceutical and medication delivery company, today announced the launch of its next-generation 50 mL and 100 mL V
(Date:12/4/2009)HOUSTON, Dec. 4 OrthoAccel Technologies, Inc., developers of the AcceleDent System , which is an acceleration device to enhance orthodontics, announced the availability of a new Continuing Education
(Date:12/4/2009)WILMINGTON, Del., Dec. 4 AstraZeneca (NYSE: AZN ) today announced that the US Food and Drug Administration (FDA) has approved once-daily SEROQUEL XR® (quetiapine fumarate) Extended Release Tab
Breaking Medicine Technology:Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 2Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 3Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 4AcceleDent Science is Showcased in New Continuing Education Course Published by PennWell 2AcceleDent Science is Showcased in New Continuing Education Course Published by PennWell 3AcceleDent Science is Showcased in New Continuing Education Course Published by PennWell 4US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 2US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 3US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 4US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 5US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 6US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 7US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 8US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 9Sono Tek Announces Second Quarter Results 5398 1Sono Tek Announces Second Quarter Results 5398 2Sono Tek Announces Second Quarter Results 5398 3AvMed Covers H1N1 Flu Vaccine For Members 5395 1AvMed Covers H1N1 Flu Vaccine For Members 5395 2Allscripts and Sandata Partner to Enhance Quality in Home Care Agencies Nationwide 10323 1Allscripts and Sandata Partner to Enhance Quality in Home Care Agencies Nationwide 10323 2Allscripts and Sandata Partner to Enhance Quality in Home Care Agencies Nationwide 10323 3
...LVERN, Pa., Nov. 18 Arlington Medical Resources (...r the pharmaceutical and diagnostic,imaging indust... Privigen was,sold in the U.S. during the third qu...ravenous immune globulin (IVIG) and was launched i...ated from the blood plasma of thousands,of donors ...
...ndomized study will enroll newly diagnosed, elderl...Celator Pharmaceuticals today announced that the f...e 2 clinical study of CPX-351 (Cytarabine:Daunorub...agnosed acute myeloid leukemia (AML). , , The... the Weill Medical College of Cornell University ...
Other Medicine Technology:Over $10 Million of CSL Behring's Privigen Was Sold in the U.S. During the Third Quarter of 2008 2Celator(R) Pharmaceuticals Announces Enrollment of First Patient in Phase 2 Study with CPX-351 2Celator(R) Pharmaceuticals Announces Enrollment of First Patient in Phase 2 Study with CPX-351 3
(Date:12/5/2009)NEW ORLEANS, Dec. 5 Leukemia and myeloproliferative disorders are serious and often deadly blood cancers. Research presented today at the 51st Annual Meeting of the American Society of Hematology int
(Date:12/5/2009)The MAMA campaign is a collaborative effort by the National Association of Certified Professional Midwives (NACPM), Midwives Alliance of North America (MANA), Citizens for Midwifery (CfM), Internation
(Date:12/4/2009)SAN FRANCISCO, Dec. 4 Medithrive, Inc. has won the Patient,s Choice Award as the favorite dispensary in the SF Bay Area by popular vote conducted by the online website, www.weedmaps.com. Despite on
(Date:12/4/2009)MADISON HEIGHTS, Mich., Dec. 4 The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine today announced Allergan, Inc. (NYSE: AGN ) as its February 2010 "Stock to Stud
(Date:12/4/2009)STANFORD, Calif. A new study shows that muscle cells grown in the lab can restore an intestine,s ability to squeeze shut properly. The work, performed in dogs and rats, might ultimately help treat pa
Breaking Medicine News(10 mins):Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 2Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 3Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 4Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 5Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 6Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 7Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 8Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 9Health News:AquaNatal Birth Center Gives Away a Waterbirth Package to Celebrate the Successful MAMA Campaign 2Health News:AquaNatal Birth Center Gives Away a Waterbirth Package to Celebrate the Successful MAMA Campaign 3Health News:AquaNatal Birth Center Gives Away a Waterbirth Package to Celebrate the Successful MAMA Campaign 4Health News:BetterInvesting Magazine Releases February Stock to Study and Undervalued Stock Choicesfor Investors' Informational and Educational Use 2Health News:Muscle cell infusion shown to strengthen sphincters in animals in Stanford study 2Health News:Muscle cell infusion shown to strengthen sphincters in animals in Stanford study 3Health News:Muscle cell infusion shown to strengthen sphincters in animals in Stanford study 4
... , , , , Wheelock becomes chair, McNerney is v... EAGAN, Minn., Feb. 13 The Blue Cross and Blue Sh...as elected new board leaders. Pamela Wheelock, vic...cently held the position of vice chair. Wheelock h...
...nds even without weight loss, general health, func...thDay News) -- Even if it doesn,t help them lose w... quality of life, a U.S. study shows. , It include... expenditure of 4 kilocalories per kilogram (2.2 p...
...RTLAND, Oregon, Feb. 13 Women,s Healthcare Associ... midwifery, maternal fetal,medicine and genetics p... has,been honored by the American Academy of Nurse..., received the honor in a recent ceremony. America...
... - Dr. Tommy Tomizawa of UCLA Medical Center will ...cs may be beneficial to the elderly - , , TORRANC...ulation expected to climb over 300% in the next 50...mizawa, Assistant Professor at the David Geffen Me...
... highest ionized serum calcium 3 times more likely...(HealthDay News) -- A newly identified biomarker f... to decide whether or not to undergo treatment for...ith the lowest levels, said researchers at Wake Fo...
...E, Feb. 13 Seattle native composer Mateo Messina,... has recently won a Grammy award for Best Compilat... Other Visual Media. The team of talented artists ...es such as Juno and Thank You for Smoking to t...
Other Medicine News:Health News:Blue Cross Board of Trustees Elects New Leadership 2Health News:Exercise Boosts Quality of Life in Postmenopausal Women 2Health News:Women's Healthcare Associates Midwife Winner of American Academy of Nurse Practitioners State Award of Excellence 2Health News:The Effects of Probiotics on the Aging Digestive Tract to be Presented at Nutracon 2009 2Health News:Researchers ID Biomarker for Fatal Prostate Cancer 2Health News:Seattle Native Composer's Work Wins Grammy Award 2
...ratory and a worldwide leader in innovative labora...nsive test menu of highly complex and unique medic... by the University of Utah, ARUP Laboratories' cli...sity teaching hospitals and children's hospitals, ...
...ratory and a worldwide leader in innovative labora...nsive test menu of highly complex and unique medic... by the University of Utah, ARUP Laboratories' cli...sity teaching hospitals and children's hospitals, ...
...ratory and a worldwide leader in innovative labora...nsive test menu of highly complex and unique medic... by the University of Utah, ARUP Laboratories' cli...sity teaching hospitals and children's hospitals, ...
...ratory and a worldwide leader in innovative labora...nsive test menu of highly complex and unique medic... by the University of Utah, ARUP Laboratories' cli...sity teaching hospitals and children's hospitals, ...
Medicine Products: